Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18430567 | 1.00 | PLA2G4A (0.36) | PLA2G4AL3MBTL1FBP1NR1I2HSPA5 | |
| SCHEMBL21217035 | 1.00 | PLA2G4A (0.36) | PLA2G4AL3MBTL1FBP1NR1I2HSPA5 | |
| SCHEMBL18948435 | 1.00 | PLA2G4A (0.36) | PLA2G4AL3MBTL1FBP1NR1I2HSPA5 | |
| SCHEMBL29325457 | 1.00 | PLA2G4A (0.36) | PLA2G4AL3MBTL1FBP1NR1I2HSPA5 | |
| SCHEMBL20098093 | 0.98 | PLA2G4A (0.35) | PLA2G4AL3MBTL1FBP1NR1I2HSPA5 | |
| SCHEMBL28578071 | 0.95 | L3MBTL1 (0.34) | PLA2G4AL3MBTL1FBP1HSPA5CTSK | |
| SCHEMBL29865290 | 0.93 | NR1I2 (0.38) | PLA2G4AL3MBTL1FBP1NR1I2 | |
| SCHEMBL12193817 | 0.85 | FBP1 (0.37) | FBP1HSPA5SLC6A2SLC6A4 | |
| SCHEMBL1670553 | 0.84 | CA2 (0.39) | PLA2G4AL3MBTL1 | |
| SCHEMBL7763980 | 0.83 | PLA2G4A (0.34) | PLA2G4AL3MBTL1FBP1HSPA5CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | TEON THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| US-11306081-B2 | Phenylacetamides as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210147407-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| US-9760030-B2 | Electrophotographic photosensitive member, process cartridge, and electrophotographic apparatus | CANON KABUSHIKI KAISHA (JP) | 2017-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147407-A1 | PHENYLACETAMIDES AS INHIBITORS OF ROCK | MYLK, ROCK1, ROCK2 | PLA2G4A 430/4885L3MBTL1 4341/4885FBP1 2395/4885 |
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA3 | PLA2G4A 90/4885L3MBTL1 3210/4885FBP1 1297/4885 |
| US-11306081-B2 | Phenylacetamides as inhibitors of rock | MYLK, ROCK1, ROCK2 | PLA2G4A 430/4885L3MBTL1 4341/4885FBP1 2395/4885 |
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | PLA2G4A 996/4885L3MBTL1 4658/4885FBP1 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.